Immune response in severe infection: Could life-saving drugs be potentially harmful?

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Surbatovic, Maja ^a   Jevdjic, Jasna ^b,c   Veljovic, Milic ^a   Popovic, Nada ^d,e   Djordjevic, Dragan ^a   Radakovic, Sonja ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b CLINICAL CENTER KRAGUJEVAC   (Serbia)

^c University of Kragujevac Medical Faculty   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CEPHALOSPORIN DERIVATIVE; DOBUTAMINE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEVOSIMENDAN; MESSENGER RNA; NITRIC OXIDE SYNTHASE INHIBITOR; PENICILLIN DERIVATIVE; PROCALCITONIN; PROPRANOLOL; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CATECHOLAMINE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG ERUPTION; ENERGY YIELD; HERXHEIMER REACTION; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION; MACROPHAGE; MITOCHONDRIAL RESPIRATION; MONOCYTE; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; OXYGEN CONSUMPTION; POLYMORPHONUCLEAR CELL; PRACTICE GUIDELINE; PRESCRIPTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SEPSIS; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA; ADVERSE DRUG REACTION; CRITICAL ILLNESS; IMMUNOLOGY;

ANTI-BACTERIAL AGENTS; CATECHOLAMINES; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFECTION;

EID: 84886645363     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/961852     Document Type: Review

References (65)

1. Surbatovic M., Radakovic S., Jovanovic K., New strategies in multiple organ dysfunction syndrome therapy for sepsis. Srpski Arhiv za Celokupno Lekarstvo 2005 133 379 383
2. Surbatovic M., Filipovic N., Slavkovic Z., Infection and inflammation in sepsis. Vojnosanitetski Pregled 2006 63 163 168
3. Djordjevic D., Surbatovic M., Ugrinovic D., New aspects of sepsis pathophysiology in critically ill. Vojnosanitetski Pregled 2012 69 58 68
4. Surbatovic M., Filipovic N., Army S., Radakovic S., Stankovic N., Slavkovic Z., Immune cytokine response in combat casualties: blast or explosive trauma with or without secondary sepsis. Military Medicine 2007 172 2 190 195 2-s2.0-33846929878 (Pubitemid 46239024)
5. Ulloa L., Tracey K. J., The "cytokine profile": a code for sepsis. Trends in Molecular Medicine 2005 11 2 56 63 2-s2.0-13244288781 10.1016/j.molmed.2004.12.007 (Pubitemid 40193483)
6. Hoesel L. M., Ward P. A., Mechanisms of inflammatory response syndrome in sepsis. Drug Discovery Today 2004 1 3 345 350 2-s2.0-23744507023 10.1016/j.ddmec.2004.11.003 (Pubitemid 41128960)
7. Opal S. M., The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. International Journal of Medical Microbiology 2007 297 5 365 377 2-s2.0-34547515353 10.1016/j.ijmm.2007. 03.006 (Pubitemid 47188050)
8. Klune J. R., Dhupar R., Cardinal J., Billiar T. R., Tsung A., HMGB1: endogenous danger signaling. Molecular Medicine 2008 14 7-8 476 484 2-s2.0-48149096398 10.2119/2008-00034.Klune
9. Matzinger P., The danger model: a renewed sense of self. Science 2002 296 5566 301 305 2-s2.0-0037066427 10.1126/science.1071059 (Pubitemid 34303674)
10. Hirsiger S., Simmen H. P., Werner C. M. L., Danger signals activating the immune response after trauma. Mediators of Inflammation 2012 2012 10 315941 10.1155/2012/315941
11. Bonawitz N. D., Clayton D. A., Shadel G. S., Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Molecular Cell 2006 24 6 813 825 2-s2.0-33845744837 10.1016/j.molcel.2006.11.024 (Pubitemid 46001607)
12. Nduka O. O., Parrillo J. E., The pathophysiology of septic shock. Critical Care Clinics 2009 25 4 677 702 2-s2.0-70350475286 10.1016/j.ccc.2009. 08.002
13. Surbatovic M., Radakovic S., Tumor necrosis factor-alpha levels early in severe acute pancreatitis: is there predictive value regarding severity and outcome? Journal of Clinical Gastroenterology 2013 47 637 643
14. Surbatovic M., Grujic K., Cikota B., Jevtic M., Filipovic N., Romic P., Strelic N., Magic Z., Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients. Journal of Critical Care 2010 25 3 542.e1 542.e8 2-s2.0-84055218634 10.1016/j.jcrc.2009.12.003
15. Cavaillon J.-M., Annane D., Compartmentalization of the inflammatory response in sepsis and SIRS. Journal of Endotoxin Research 2006 12 3 151 170 2-s2.0-33745932547 10.1179/096805106X102246 (Pubitemid 47487521)
16. Hotchkiss R. S., Swanson P. E., Freeman B. D., Tinsley K. W., Cobb J. P., Matuschak G. M., Buchman T. G., Karl I. E., Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Critical Care Medicine 1999 27 7 1230 1251 2-s2.0-0032770246 10.1097/00003246-199907000-00002 (Pubitemid 29379358)
17. Fink M. P., Evans T. W., Mechanisms of organ dysfunction in critical illness: report from a Round table Conference held in Brussels. Intensive Care Medicine 2002 28 3 369 375 2-s2.0-0036122668 10.1007/s00134-001-1205-2 (Pubitemid 34230662)
18. Abraham E., Singer M., Mechanisms of sepsis-induced organ dysfunction. Critical Care Medicine 2007 35 10 2408 2416 2-s2.0-34748927007 10.1097/01.CCM.0000282072.56245.91 (Pubitemid 47476242)
19. Hotchkiss R. S., Monneret G., Payen D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. The Lancet Infectious Diseases 2013 13 260 268
20. Vincent J.-L., Rello J., Marshall J., Silva E., Anzueto A., Martin C. D., Moreno R., Lipman J., Gomersall C., Sakr Y., Reinhart K., International study of the prevalence and outcomes of infection in intensive care units. The Journal of the American Medical Association 2009 302 21 2323 2329 2-s2.0-72249087115 10.1001/jama.2009.1754
21. Ward P. A., Immunosuppression in sepsis. The Journal of the American Medical Association 2011 306 23 2618 2619 2-s2.0-84255193988 10.1001/jama.2011.1831
22. Morris A. C., Simpson A. J., Walsh T. S., Vincent J. L., Hyperinflammation and mediators of immune suppression in critical illness. Annual Update in Intensive Care and Emergency Medicine 2013 Berlin, Germany Springer 135 144
23. Brown K. A., Brain S. D., Pearson J. D., Edgeworth J. D., Lewis S. M., Treacher D. F., Neutrophils in development of multiple organ failure in sepsis. The Lancet 2006 368 9530 157 169 2-s2.0-33745617094 10.1016/S0140-6736(06)69005- 3 (Pubitemid 43994173)
24. Conway Morris A., Kefala K., Wilkinson T. S., Dhaliwal K., Farrell L., Walsh T., Mackenzie S. J., Reid H., Davidson D. J., Haslett C., Rossi A. G., Sallenave J.-M., Simpson A. J., C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. American Journal of Respiratory and Critical Care Medicine 2009 180 1 19 28 2-s2.0-67249123446 10.1164/rccm.200812- 1928OC
25. Morris A. C., Brittan M., Wilkinson T. S., McAuley D. F., Antonelli J., McCulloch C., Barr L. C., McDonald N. A., Dhaliwal K., Jones R. O., Mackellar A., Haslett C., Hay A. W., Swann D. G., Anderson N., Laurenson I. F., Davidson D. J., Rossi A. G., Walsh T. S., Simpson A. J., C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. Blood 2011 117 19 5178 5188 2-s2.0-79955966974 10.1182/blood-2010-08-304667
26. Xiao W., Mindrinos M. N., Seok J., A genomic storm in critically injured humans. The Journal of Experimental Medicine 2011 208 2581 2590
27. Dellinger P. R., Levy M. M., Rhodes A., Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine 2013 41 580 637
28. Kumar A., Roberts D., Wood K. E., Light B., Parrillo J. E., Sharma S., Suppes R., Feinstein D., Zanotti S., Taiberg L., Gurka D., Kumar A., Cheang M., Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine 2006 34 6 1589 1596 2-s2.0-33744527833 10.1097/01.CCM.0000217961.75225. E9 (Pubitemid 43810035)
29. Prowle J. R., Heenen S., Singer M., Infection in the critically ill-questions we should be asking. Journal of Antimicrobial Chemotherapy 2011 66 supplement 2 ii3 ii10 2-s2.0-79952586750 10.1093/jac/dkq517
30. Labelle A., Juang P., Reichley R., The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment. Critical Care Medicine 2012 40 216 222
31. Kethireddy S., Kumar A., Mortality due to septic shock following early, appropriate antibiotic therapy: can we do better? Critical Care Medicine 2012 40 2228 2229
32. McGregor J. C., Rich S. E., Harris A. D., Perencevich E. N., Osih R., Lodise T. P. Jr., Miller R. R., Furuno J. P., A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clinical Infectious Diseases 2007 45 3 329 337 2-s2.0-34547129800 10.1086/519283 (Pubitemid 47101029)
33. Clec'h C., Timsit J.-F., De Lassence A., Azoulay E., Alberti C., Garrouste-Orgeas M., Mourvilier B., Troche G., Tafflet M., Tuil O., Cohen Y., Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Medicine 2004 30 7 1327 1333 2-s2.0-3242688631 (Pubitemid 38951714)
34. Harbarth S., Nobre V., Pittet D., Does antibiotic selection impact patient outcome? Clinical Infectious Diseases 2007 44 1 87 93 2-s2.0-33845708554 10.1086/510075 (Pubitemid 44968991)
35. Corona A., Bertolini G., Lipman J., Antibiotic use and impact on outcome from bacteraemic critical illness: the Bacteraemia Study in Intensive Care (BASIC). Journal of Antimicrobial Chemotherapy 2010 65 1276 1285
36. Puskarich M. A., Trzeciak S., Shapiro N. I., Arnold R. C., Horton J. M., Studnek J. R., Kline J. A., Jones A. E., Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Critical Care Medicine 2011 39 9 2066 2071 2-s2.0-80051951653 10.1097/CCM.0b013e31821e87ab
37. Singer M., Glynne P., Treating critical illness: the importance of first doing no harm. PLoS Medicine 2005 2 6, article e167 2-s2.0-22144445679 10.1371/journal.pmed.0020167 (Pubitemid 40973501)
38. Brealey D., Brand M., Hargreaves I., Heales S., Land J., Smolenski R., Davies N. A., Cooper C. E., Singer M., Association between mitochondrial dysfunction and severity and outcome of septic shock. The Lancet 2002 360 9328 219 223 2-s2.0-0037142987 10.1016/S0140-6736(02)09459-X (Pubitemid 34804650)
39. Brealey D., Karyampudi S., Jacques T. S., Novelli M., Stidwill R., Taylor V., Smolenski R. T., Singer M., Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2004 286 3 R491 R497 2-s2.0-1342331785 (Pubitemid 38252613)
40. Boulos M., Astiz M. E., Barua R. S., Osman M., Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Critical Care Medicine 2003 31 2 353 358 2-s2.0-0037324056 10.1097/01.CCM.0000050074.82486.B2 (Pubitemid 36232925)
41. Singer P. M., De Santis V., Vitale D., Jeffcoate W., Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inaflammation. The Lancet 2004 364 9433 545 548 2-s2.0-4043128084 10.1016/S0140-6736(04)16815-3 (Pubitemid 39070417)
42. Hotchkiss R. S., Karl I. E., The pathophysiology and treatment of sepsis. The New England Journal of Medicine 2003 348 2 138 150 2-s2.0-0037426726 10.1056/NEJMra021333 (Pubitemid 36056721)
43. Carre J. E., Orban J. C., Re L., Survival in critical illness is associated with early activation of mitochondrial biogenesis. American Journal of Respiratory and Critical Care Medicine 2010 182 745 751
44. Lepper P. M., Held T. K., Schneider E. M., Bölke E., Gerlach H., Trautmann M., Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Medicine 2002 28 7 824 833 2-s2.0-0036020289 10.1007/s00134-002-1330-6 (Pubitemid 34762215)
45. Heer C., Stuertz K., Reinert R. R., Mäder M., Nau R., Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin. Infection 2000 28 1 13 20 2-s2.0-0033973047 10.1007/s150100050004 (Pubitemid 30093202)
46. Griffin G. E., Cytokines involved in human septic shock-the model of the Jarisch-Herxheimer reaction. Journal of Antimicrobial Chemotherapy 1998 41, supplement A25 A29 2-s2.0-0031985983
47. Bouadma L., Luyt C.-E., Tubach F., Cracco C., Alvarez A., Schwebel C., Schortgen F., Lasocki S., Veber B., Dehoux M., Bernard M., Pasquet B., Régnier B., Brun-Buisson C., Chastre J., Wolff M., Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet 2010 375 9713 463 474 2-s2.0-75949113583 10.1016/S0140-6736(09)61879-1
48. Jensen J. U., Hein L., Lundgren B., Bestle M. H., Mohr T. T., Andersen M. H., Thornberg K. J., Løken J., Steensen M., Fox Z., Tousi H., Søe-Jensen P., Lauritsen A. Ø., Strange D., Petersen P. L., Reiter N., Hestad S., Thormar K., Fjeldborg P., Larsen K. M., Drenck N. E., Østergaard C., Kjær J., Grarup J., Lundgren J. D., Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011 39 9 2048 2058 2-s2.0-80051921479 10.1097/CCM.0b013e31821e8791
49. Singer M., The key advance in the treatment of sepsis in the last 10 years. doing less. Critical Care 2006 10 1, article 122 2-s2.0-34447547884 10.1186/cc4849 (Pubitemid 47079823)
50. 2 utilization in heart failure. Cardiovascular Research 2002 53 2 392 404 2-s2.0-0036162364 10.1016/S0008-6363(01)00490-4 (Pubitemid 34117690)
51. Bergmann M., Sautnet T., Immunomodulatory effects of vasoactive catecholamines. Die Wiener klinische Wochenschrift 2002 114 752 761
52. Arcaroli J., Yang K.-Y., Yum H.-K., Kupfner J., Pitts T. M., Park J. S., Strassheim D., Abraham E., Effects of catecholamines on kinase activation in lung neutrophils after hemorrhage or endotoxemia. Journal of Leukocyte Biology 2002 72 3 571 579 2-s2.0-0036745071
53. Levy B., Mansart A., Bollaert P.-E., Franck P., Mallie J.-P., Effects of epinephrine and norepinephrine on hemodynamics, oxidative metabolism, and organ energetics in endotoxemic rats. Intensive Care Medicine 2003 29 2 292 300 2-s2.0-0347296030 (Pubitemid 36384420)
54. Lyte M., Freestone P. P. E., Neal C. P., Olson B. A., Haigh R. D., Bayston R., Williams P. H., Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. The Lancet 2003 361 9352 130 135 2-s2.0-0037431758 10.1016/S0140-6736(03)12231-3 (Pubitemid 36092017)
55. Freestone P. P., Williams P. H., Haigh R. D., Maggs A. F., Neal C. P., Lyte M., Growth stimulation of intestinal commensal Escherichia coli by catecholamines: a possible contributory factor in trauma-induced sepsis. Shock 2002 18 5 465 470 2-s2.0-0036835441
56. Oberbeck R., Catecholamines: physiological immunomodulators during health and illness. Current Medicinal Chemistry 2006 13 17 1979 1989 2-s2.0-33745745761 10.2174/092986706777584997
57. Lünemann J. D., Buttgereit F., Tripmacher R., Baerwald C. G. O., Burmester G.-R., Krause A., Norepinephrine inhibits energy metabolism of human peripheral blood mononuclear cells via adrenergic receptors. Bioscience Reports 2001 21 5 627 635 2-s2.0-0035744808 10.1023/A:1014768909442 (Pubitemid 34816192)
58. Singer M., Catecholamine treatment for shock-equally good or bad? The Lancet 2007 370 9588 636 637 2-s2.0-34548014479 10.1016/S0140-6736(07)61317-8 (Pubitemid 47285300)
59. Dünser M. W., Takala J., Ulmer H., Mayr V. D., Luckner G., Jochberger S., Daudel F., Lepper P., Hasibeder W. R., Jakob S. M., Arterial blood pressure during early sepsis and outcome. Intensive Care Medicine 2009 35 7 1225 1233 2-s2.0-67649362506 10.1007/s00134-009-1427-2
60. Ackland G. L., Yao S. T., Rudiger A., Dyson A., Stidwill R., Poputnikov D., Singer M., Gourine A. V., Cardioprotection, attenuated systemic inflammation, and survival benefit of β 1-adrenoceptor blockade in severe sepsis in rats. Critical Care Medicine 2010 38 2 388 394 2-s2.0-74949120243 10.1097/CCM.0b013e3181c03dfa
61. Hagiwara S., Iwasaka H., Maeda H., Noguchi T., Landiolol, an ultrashort-acting β 1-adrenoceptor antagonist, has protective effects in an lps-induced systemic inflammation model. Shock 2009 31 5 515 520 2-s2.0-67649342816 10.1097/SHK.0b013e3181863689
62. Gore D. C., Wolfe R. R., Hemodynamic and metabolic effects of selective β 1 adrenergic blockade during sepsis. Surgery 2006 139 5 686 694 2-s2.0-33646396793 10.1016/j.surg.2005.10.010
63. Schmittinger C. A., Dünser M. W., Haller M., Ulmer H., Luckner G., Torgersen C., Jochberger S., Hasibeder W. R., Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Critical Care 2008 12 4, article R99 2-s2.0-50549084025 10.1186/cc6976
64. Jeschke M. G., Norbury W. B., Finnerty C. C., Branski L. K., Herndon D. N., Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. Journal of Trauma 2007 62 3 676 681 2-s2.0-34147133713 10.1097/TA.0b013e318031afd3 (Pubitemid 46568873)
65. Singer M., Matthay M., Clinical review: thinking outside the box-an iconoclastic view of current practice. Critical Care 2011 15, article R225